24 completed, 10 unknown, 7 recruiting, 6 active not recruiting. 22 Phase 2, 19 Phase 1, 8 Not applicable, 4 Phase 3, 1 Early Phase 1.
Follow Carcinoma, Pancreatic Ductal: new trials by email Literature Review of Carcinoma, Pancreatic Ductal trials Research Report on Carcinoma, Pancreatic Ductal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa) CD318-CAR-T cells - Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 38 | 2026-07-01 | 2025-09-03 |
| Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma Relacorilant, Nab-paclitaxel, Gemcitabine - Adenocarcinoma, Carcinoma, Pancreatic Ductal | Phase 2 | Recruiting | Corcept Therapeutics | 80 | 2026-01-27 | 2026-09-25 |
| Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer Acoustic Cluster Therapy, Modified FOLFIRINOX - Locally Advanced Pancreatic Adenocarcinoma | Phase 2 | Recruiting | EXACT Therapeutics AS | 25 | 2025-06-19 | 2026-10-13 |
| A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies PF-08046037, sasanlimab - Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal | Phase 1 | Terminated | Pfizer | 8 | 2025-05-06 | 2026-04-23 |
| Using Tumor Models to Determine Treatments Cobimetinib, Ponatinib, Brigatinib - Pancreatic Ductal Carcinoma, Advanced Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 25 | 2025-04-07 | 2026-06-23 |
| A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. PF-07985045, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms | Phase 1 | Terminated | Pfizer | 30 | 2024-12-10 | 2026-05-22 |
| A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS Endoscopic ultrasound, EUS-Fine needle aspiration - Carcinoma, Pancreatic Ductal | Not yet recruiting | Peking Union Medical College Hospital | 900 | 2024-12-01 | 2024-04-09 | |
| Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin - Carcinoma, Pancreatic Ductal | Phase 2 | Not yet recruiting | Ruijin Hospital | 20 | 2024-09-01 | 2024-08-27 |
| A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. PF-07934040, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms | Phase 1 | Active not recruiting | Pfizer | 64 | 2024-06-27 | 2026-10-13 |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors RMC-6236, mFOLFOX6 regimen, bevacizumab - Colorectal Cancer, CRC | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 1130 | 2024-05-24 | 2026-09-22 |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors Elironrasib, Daraxonrasib - Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 534 | 2023-11-14 | 2026-09-22 |
| Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC, Biomarkers of tumor signatures (translational studies) - Carcinoma, Pancreatic Ductal, Prognosis | Not applicable | Active not recruiting | Institut Curie | 79 | 2022-12-12 | 2026-10-01 |
| Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors RMC-6291 - Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 | Active not recruiting | Revolution Medicines, Inc. | 222 | 2022-09-19 | 2026-05-15 |
| Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy Resection, No Resection - Carcinoma, Pancreatic Ductal | Unknown | BUSQUETS, JULI | 100 | 2022-09-01 | 2022-08-05 | |
| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) Pleural Effusion, Malignant, Ascites, Malignant | Completed | Travera Inc | 72 | 2022-07-15 | 2026-04-13 | |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS RMC-6236 - Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 754 | 2022-05-31 | 2026-05-15 |
| A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors vobramitamab duocarmazine, lorigerlimab - Advanced Solid Tumor, Castration-Resistant Prostatic Cancer | Phase 1 | Completed | MacroGenics | 31 | 2022-04-19 | 2025-10-14 |
| Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation JAB-21822, JAB-3312 - KRAS P.G12C, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Allist Pharmaceuticals, Inc. | 240 | 2022-04-14 | 2026-08-13 |
| EUS Shear Wave for Solid Pancreatic Lesions. Pancreas EUS shear wave, Pancreas EUS-elastography and EUS-guided biopsy - Pancreas Neoplasm, Pancreatitis | Unknown | Instituto Ecuatoriano de Enfermedades Digestivas | 25 | 2021-10-01 | 2022-01-04 | |
| A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer Modified FOLFIRINOX Regimen, NanoKnife System - Stage III Pancreatic Cancer | Phase 3 | Active not recruiting | Angiodynamics, Inc. | 528 | 2021-02-23 | 2025-02-12 |
Showing 20 of 57. Sign in to see all of them.
Pancreatic Neoplasms (25) · Carcinoma, Non-Small-Cell Lung (12) · Colorectal Neoplasms (11) · Colonic Neoplasms (7) · Lung Neoplasms (6) · Ovarian Neoplasms (6) · Neoplasm Metastasis (5) · Rectal Neoplasms (5) · Stomach Neoplasms (5) · Gastrointestinal Neoplasms (4) · Melanoma (4) · Pancreatic Diseases (4) · Squamous Cell Carcinoma of Head and Neck (4) · Adenocarcinoma (3)
Carcinoma, Ductal (57) · Neoplasms, Ductal, Lobular, and Medullary (57) · Digestive System Diseases (56) · Endocrine System Diseases (56) · Neoplasms by Histologic Type (56) · Neoplasms, Glandular and Epithelial (56) · Carcinoma (55) · Digestive System Neoplasms (55) · Endocrine Gland Neoplasms (55) · Adenocarcinoma (54) · Neoplasms (54) · Neoplasms by Site (54) · Pancreatic Diseases (53) · Pancreatic Neoplasms (32) · Gastrointestinal Diseases (14)
Gemcitabine (15) · 130-nm albumin-bound paclitaxel (10) · Albumin-Bound Paclitaxel (7) · Oxaliplatin (5) · Carboplatin (4) · Fluorouracil (4) · Leucovorin (4) · Paclitaxel (4) · Bevacizumab (3) · Cetuximab (3) · Cisplatin (3) · Irinotecan (2) · MK-4721 (2) · PEGPH20 (2) · Pemetrexed (2)
Pfizer (4) · Revolution Medicines, Inc. (4) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Allist Pharmaceuticals, Inc. (2) · Angiodynamics, Inc. (2) · Fudan University (2) · Halozyme Therapeutics (2) · Sumitomo Pharma America, Inc. (2) · University Health Network, Toronto (2) · Agensys, Inc. (1) · Astellas Pharma Inc (1) · AstraZeneca (1) · BUSQUETS, JULI (1) · Celgene (1) · Changhai Hospital (1)
United States (30) · China (9) · Spain (9) · France (8) · Canada (7) · Italy (7) · Netherlands (7) · Germany (6) · Australia (5) · South Korea (5) · Puerto Rico (4) · Taiwan (4) · United Kingdom (4) · Austria (3) · Belgium (3)
Revolution Medicines, Inc. (3) · Baiyong Shen, PhD,MD (1) · Bernard Huber, Dr. (1) · Carlos Robles-Medranda, MD FASGE (1) · Danny Nguyen (1) · David Ryan, MD (1) · Denise Casey, M.D. (1) · Dirk Strumberg, Prof.Dr.med. (1) · Donald M Mathews, M.D. (1) · Eva Hofsli, md phd (1) · G. Paul Wright, MD (1) · Gordan Bray, M.D., Ph.D (1)
PMID 34233640, PMID 37590355, PMID 40056080, PMID 21306953, PMID 22038501, PMID 24054418, PMID 24368638, PMID 25141915, PMID 25175768, PMID 28932088, PMID 29192743, PMID 29232172, PMID 29288237, PMID 31481506, PMID 32299515, PMID 32519972, PMID 33114652, PMID 33124700, PMID 33478521, PMID 33648879, PMID 34477122, PMID 34520686, PMID 37195787, PMID 37489066, PMID 38353966, PMID 38589574, PMID 38593348, PMID 38701690, PMID 39970867, PMID 40333694, PMID 41325755, PMID 42090791, PMID 42685317
2025 (2), 2009 (1), 2014 (1), 2015 (1), 2019 (1)